Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardInsightsMedcastPeers & Perspectives
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Bryant Furlow

Advertisement

Articles by Bryant Furlow

 MG - stock.adobe.com

Quiz: NCCN 2019 prostate Ca guideline emphasizing germline testing

ByBryant Furlow
August 1st 2019
frank peters - stock.adobe.com

Quiz: AUA castration-resistant PCa guideline amendment

ByBryant Furlow
July 8th 2019

These six questions are meant to test your knowledge of the updates to the AUA's treatment guideline for castration-resistant prostate cancer.

Advertisement

Latest Updated Articles

  • frank peters - stock.adobe.com
    Quiz: AUA castration-resistant PCa guideline amendment

    Published: July 8th 2019 | Updated:

  •  MG - stock.adobe.com
    Quiz: NCCN 2019 prostate Ca guideline emphasizing germline testing

    Published: August 1st 2019 | Updated:



Advertisement
Advertisement

Trending on Urology Times

1

CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC

2

Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC

3

Choosing salvage therapy after prostate cancer focal ablation

4

SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort

5

Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do not sell my Personnal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us